Analytical Data
-
基因名
ErbB3
- Application
-
别名
ErbB3；HER3NEU;Receptor tyrosine-Protein kinase erbB-3
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P21860
-
表达区间
20-643aa
-
氨基酸序列
SEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTG HNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFV MLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRD RDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCF GPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLT FQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKM CEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLN GDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIG GRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLN WTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLS CRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSG SDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQ GCKGPELQDCLGQTLVLIGKTHLT
-
分子量
95 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ErbB3, also known as human epidermal growth factor receptor 3 (HER3), is a member of the ErbB receptor family, which plays a crucial role in the regulation of cell growth, survival, and differentiation. Its significance in cancer biology has garnered increasing attention due to its unique ability to heterodimerize with other ErbB family members, such as ErbB2 and ErbB4, thereby promoting oncogenic signaling pathways. Unlike other ErbB receptors, ErbB3 has a kinase-deficient domain, which limits its signaling capabilities; however, it is vital for the activation of downstream signaling cascades such as the PI3K/Akt pathway when paired with kinase-active partners. This makes ErbB3 a potential therapeutic target, particularly in cancers where it is overexpressed or activated, such as breast, lung, and gastric cancers. The study of recombinant ErbB3 proteins has become essential for understanding its role in tumorigenesis and for the development of targeted therapies. By utilizing recombinant DNA technology, researchers can produce ErbB3 proteins that are structurally and functionally relevant, enabling detailed investigations into their interactions, post-translational modifications, and functional characteristics. These studies are critical for elucidating the mechanisms of ErbB3-mediated signaling and for identifying novel drug targets or combination therapies that can disrupt its function in cancer cells, thereby enhancing therapeutic efficacy and overcoming drug resistance. Overall, understanding ErbB3 through recombinant protein studies holds promise for advancing cancer treatment strategies and improving patient outcomes.
